Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DEFENSE HEALTH AGENCY

Contract Value

Not provided

Codes & Classification
Solicitation Number

HT9402-26-Q-9301

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

NONE

Place of Performance

San Antonio, Texas, UNITED STATES

SourceSAM
Documents5
The Defense Health Agency (DHA), operating under the Department of Defense, has issued a solicitation (Procurement Identifier: HT9402-26-Q-9301) for the establishment of Uniform Formulary Blanket Purchase Agreements (UF BPAs) and Uniform Formulary Additional Discount Program Agreements (UF ADP) as part of its statutory mandate to provide an integrated pharmacy benefits program for the Military Health System (MHS). This procurement is driven by the requirements set forth in 10 U.S.C. § 1074g and its implementing regulation, 32 CFR Section 199.21, which direct the Department of War (DoW) to ensure the clinical and cost effectiveness of pharmaceutical agents available to military beneficiaries. The primary objective of this solicitation is to obtain competitive quotations from industry for pharmaceutical agents within specific drug classes identified for potential placement on the DoW Uniform Formulary (UF). The UF is a critical component of the MHS pharmacy benefits program, categorizing drugs as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF) for cost-sharing and clinical use purposes. The selection process is informed by the recommendations of the DoW Pharmacy and Therapeutics (P&T) Committee, which evaluates the clinical and cost effectiveness of agents within each therapeutic class. For the August 2026 P&T Committee meeting, the following drug classes and agents are under review: a. ADHD Agents – Stimulants: - AZSTARYS - COTEMPLA XR-ODT - DYANAVEL XR - JORNAY PM - MYDAYIS - QUILLICHEW ER - QUILLIVANT XR - XELSTRYM b. Oncological Agents – BRAF-MEK Inhibitors: - BRAFTOVI - COTELLIC - MEKINIST - MEKTOVI - TAFINLAR - ZELBORAF The solicitation package, including the RFQ and appendices for UF BPA and UF ADP, provides detailed instructions, submission requirements, and deadlines. A pre-quotation teleconference is scheduled for May 13, 2026, with further details outlined in Part 2.4 of the RFQ. Interested parties are encouraged to review all attached documents for comprehensive guidance on participation. This procurement is classified under NAICS Code 325412 (Pharmaceutical Preparation Manufacturing) and Product Service Code 6505. There are no set-aside restrictions, making this opportunity open to all qualified vendors. The place of performance is San Antonio, Texas, United States. The contracting entity is the Defense Health Agency, a federal office within the Department of Defense. The primary point of contact for this solicitation is Tracy Banks ([email protected]), with Keith Marasigan ([email protected]) serving as the secondary contact. The solicitation was posted on July 5, 2026, and remains active, with responses due by June 29, 2026. All relevant documents and attachments are accessible via the official SAM.gov opportunity listing (Opportunity ID: 38fb9a33978f4e67b037c64798e35732). Contractors with capabilities in pharmaceutical preparation manufacturing, particularly those offering agents within the specified ADHD stimulant and BRAF-MEK inhibitor classes, are encouraged to evaluate this opportunity. The procurement seeks to establish agreements that will support the MHS in delivering clinically effective and cost-efficient pharmaceutical care to military beneficiaries, in alignment with federal law and DoD policy.